Composition comprising EMP3 inhibitor for inhibiting growth of cancer stemcell and use thereof
AssigneeKorea Atomic Energy Research Institute
InventorsIn Gyu Kim, Rae Kwon Kim, Yeon Jee Kahm
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition for inhibiting the growth of cancer stem cells and a use thereof. When treated with the EMP3 inhibitor, cancer stem cells expressing ALDH1 decrease in self-renewal potential, invasiveness, and migration ability and thus are restrained from growing, whereby cancer having stemness properties, which are resistant to conventional anticancer therapies, can be effectively treated.
Claims10
A method for inhibiting growth of cancer stem cells, the method comprising a step of administering an epithelial membrane protein 3 (EMP3) inhibitor to a subject in need thereof,
- wherein the cancer stem cells are cancer cells in which an aldehyde dehydrogenase 1 (ALDH1) protein is overexpressed, or an activity of the ALDH1 protein is positive, wherein the ALDH1 protein is a cancer stem cell marker,
- the EMP3 inhibitor is an oligonucleotide inhibiting the expression of EMP3 genes,
- wherein the oligonucleotide inhibiting the expression of EMP3 genes is a siRNA, which is specific for EMP3 mRNA, wherein the siRNA is an oligonucleotide set forth in SEQ ID NO:
- 2 or SEQ ID NO:
- 3.
A method for treating cancer, the method comprising a step of administering an epithelial membrane protein 3 (EMP3) inhibitor to a subject in need thereof, wherein the cancer has ALDH1-overexpressing cancer stem cell properties,
- wherein the cancer stem cells are cancer cells in which an aldehyde dehydrogenase 1 (ALDH1) protein is overexpressed, or an activity of the ALDH1 protein is positive, wherein the ALDH1 protein is a cancer stem cell marker,
- the EMP3 inhibitor is an oligonucleotide inhibiting the expression of EMP3 genes,
- wherein the oligonucleotide inhibiting the expression of EMP3 genes is a siRNA, which is specific for EMP3 mRNA, wherein the siRNA is an oligonucleotide set forth in SEQ ID NO:
- 2 or SEQ ID NO:
- 3.
A method for assisting a radiation anticancer treatment, the method comprising a step of administering epithelial membrane protein 3 (EMP3) inhibitor to a subject in need thereof,
- wherein the cancer has ALDH1-overexpressing cancer stem cell properties,
- the cancer stem cells are cancer cells in which an aldehyde dehydrogenase 1 (ALDH1) protein is overexpressed, or an activity of the ALDH1 protein is positive, wherein the ALDH1 protein is a cancer stem cell marker,
- the EMP3 inhibitor is an oligonucleotide inhibiting the expression of EMP3 genes,
- wherein the oligonucleotide inhibiting the expression of EMP3 genes is a siRNA, which is specific for EMP3 mRNA, wherein the siRNA is an oligonucleotide set forth in SEQ ID NO:
- 2 or SEQ ID NO:
- 3.
A method for enhancing the sensitivity of cancer cells to radiation, the method comprising a step of administering epithelial membrane protein 3 (EMP3) inhibitor to a subject in need thereof,
- wherein the cancer cells are cells in which an aldehyde dehydrogenase 1 (ALDH1) protein is overexpressed, or an activity of the ALDH1 protein is positive, wherein the ALDH1 protein is a cancer stem cell marker,
- the EMP3 inhibitor is an oligonucleotide inhibiting the expression of EMP3 genes,
- wherein the oligonucleotide inhibiting the expression of EMP3 genes is a siRNA, which is specific for EMP3 mRNA, wherein the siRNA is an oligonucleotide set forth in SEQ ID NO:
- 2 or SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.